BIOPLUS-INTERPHEX KOREA 2024 was held in Seoul, Korea on July 10-12, 2024. The bio-pharmaceutical exhibition had keynote sessions, over 30 conferences, partnering, open innovation, and networking opportunities to expand overseas by building global business networks.
→ Biointron’s Highlighted Points:
ADCs
In early drug development, optimizing the path to first-in-human clinical trials through integrating design and de-risking candidate ADC drugs is critical to ensure the most efficient use of limited resources and tight timelines. Optimal molecule design, early risk assessment and mitigation, and early expression of the protein where key product attributes can be confirmed will help.
Considerations for accelerating the process development and manufacturing for ADCs: The conjugation process is critical to the success of an ADC, particularly reaction parameters and process control strategy. Innovative technologies include conjugation, fill finish, buffers, and stabilizers.
Digital platforms for new modalities like mRNA, ADC, AAV, CGT for biopharmaceutical lifecycle management and ELN electronic research note platforms will enable you to digitize and analyze all data, while expanding your global business through Data Integrity.
Other Therapeutics
GLP-1-based therapies for diabetes and obesity are expected to expand beyond traditional treatments into areas such as cardiovascular disease and Parkinson's disease.
The value of mRNA-based therapeutics has been demonstrated through the development of COVID-19 vaccines, accelerating process development through cell-free synthesis.
Novel bioprocessing solutions, based on advanced synthetic fibrous materials and ligand chemistries, will help enable new bioprocessing strategies to address critical challenges in process simplification and intensification.
In 2026, the third wave of biosimilars will bring innovative production technologies, enhanced quality control, and global regulatory harmonization, especially with single-use technology
Reducing candidate risk and achieving development success with a robust developability assessment tool can help select the optimal candidate by evaluating the molecule/s physicochemical properties and hydrophobicity.
Innovation and investment opportunities in MASH (metabolic-associated steatohepatitis) including therapeutics with multi-agonists targeting GLP-1 along with GCG, GIP and others is actively underway.
We had a great time connecting with new and old faces and learning about the latest developments in the biopharma space. Our expert team is here to help you achieve your antibody development goals. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
